Reclipsen is an oral contraceptive primarily indicated for the prevention of pregnancy. The medication's therapeutic domain is relevant for conditions where functional stability becomes affected by reproductive processes. Key areas of use include the prevention of pregnancy, managing symptoms related to heavy or painful menstruation (dysmenorrhea), and supporting stability during irregular cycles. This combination may assist with managing these associated gynecological concerns.

In clinical scenarios, this approach is commonly used to provide supportive relief when symptoms interfere with daily functioning, such as reducing the severity of acne. This benefit contributes to improved comfort during symptomatic periods. This supportive care provides support that helps ease the overall symptom burden. The medication assists with maintaining functional stability, and supports general well-being during symptomatic phases.

Quick Fact: May assist with symptoms related to physical discomfort

Eligibility Map: Official Regulatory Information

Reclipsen (desogestrel and ethinyl estradiol tablets) is indicated for use in females of reproductive potential for the prevention of pregnancy.

---

Populations for whom use is Contraindicated

The medicine must not be used in patients presenting with conditions that significantly increase the risk of serious side effects, as documented in official labeling. This includes:

• Age and Smoking: Females over 35 years of age who smoke.
• Vascular/Thrombotic History: Current or history of venous or arterial thrombotic disorders (e.g., Deep Vein Thrombosis, Pulmonary Embolism, Stroke, Heart Attack), or conditions that predispose to them (e.g., severe hypertension, diabetes with vascular damage, migraine with focal aura).
• Malignancy: Current or history of breast cancer or any known or suspected sex-steroid influenced malignancy.
• Hepatic Status: Presence or history of liver tumors or severe liver disease, including severe hepatic dysfunction or steroid-dependent jaundice.
• Co-Administration: Use with the Hepatitis C drug regimen containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.
• Pregnancy: If the patient is known or suspected to be pregnant.

---

Restricted or Conditional Use

Prolonged Immobilization: Discontinuation is required at least four weeks before and for two weeks after major surgery or during a period of prolonged immobilization.

Lactation: Use is not recommended while breastfeeding, especially in the first month postpartum, as combined oral contraceptives may decrease the quality and quantity of breast milk. Initiation should be delayed until at least four weeks postpartum in non-breastfeeding women.

Reclipsen Interactions with other medicines and products

Interactions with Reclipsen (desogestrel/ethinyl estradiol) are formally documented and primarily involve changes to drug concentration or therapeutic effects, as outlined in regulatory documentation.

---

Formal Regulatory Restrictions

Co-administration is strictly contraindicated with certain combination Hepatitis C regimens, including Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir, due to the potential for significant ALT liver enzyme elevations. Furthermore, the estrogen component is prohibited for co-use with Anastrozole due to documented pharmacodynamic antagonism.

Pharmacokinetic and Substance Interactions

Interaction Type	Examples & Effect	Classification
Enzyme Induction	Carbamazepine, Rifampicin, and St. John's Wort reduce steroid plasma concentrations, potentially diminishing efficacy.	Decreased Exposure
Hormone Effect on Other Drugs	Lamotrigine clearance is increased, leading to reduced therapeutic levels.	Increased Clearance

Population and Pharmacodynamic Notes

Use of combined oral contraceptives is contraindicated in females over 35 years of age who smoke, reflecting a critical population-specific interaction restriction tied to cardiovascular risk. Additionally, the drug may decrease glucose tolerance, necessitating professional monitoring when co-administered with antidiabetic agents.

How Reclipsen Works: Mechanism of Action

Reclipsen, a combination of the progestin desogestrel (metabolized to etonogestrel) and the estrogen ethinyl estradiol, operates through multiple biological mechanisms. The components act as agonists at the Progesterone Receptor and Estrogen Receptor, triggering a negative feedback signal on the Hypothalamic-Pituitary-Ovarian (HPO) axis. This central action suppresses the release of pituitary Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH), preventing follicular maturation and the mid-cycle LH surge. The resulting physiological consequence is the inhibition of ovulation (anovulation).

Additionally, etonogestrel produces local effects on the reproductive tract. It modulates cervical glandular function, causing the cervical mucus to thicken and become less permeable to sperm. The hormones also alter the state of the endometrial lining, reducing its receptivity. Systemically, ethinyl estradiol promotes the hepatic synthesis of Sex Hormone-Binding Globulin (SHBG), which modulates the bioavailability of circulating androgens.

How Reclipsen is Used: Official Administration Guidelines

Reclipsen (desogestrel/ethinyl estradiol) is administered according to a standardized, continuous 28-day cyclic protocol. Proper use requires strict adherence to the schedule and order of tablets to ensure the correct fixed dose is taken daily.

---

Administration Overview

Instruction	Detail
Route of Administration	Oral (taken by mouth).
Dosage Schedule	One tablet daily for 28 consecutive days, without interruption.
Dose Strength	Each active tablet contains 0.15 mg desogestrel and 0.03 mg ethinyl estradiol.
Timing & Frequency	Once daily, taken at the same time every day to maintain a consistent interval.
Context	Can be taken with or without food.

---

Official Usage Protocol

The 28-day regimen is structured into two phases, with tablets taken in the order directed on the blister pack.

• Active Phase: The first 21 tablets taken are the active tablets containing the fixed hormonal combination.
• Inactive Phase: The subsequent 7 tablets are inactive reminder tablets containing no hormones.
• Continuation: A new 28-day pack must be started immediately on the day after the last tablet of the previous pack is finished.

Special Conditions:

• Order is Mandatory: The sequence in which the tablets are taken must be strictly followed.
• Vomiting/Diarrhea: If severe gastrointestinal disturbance occurs within 3–4 hours of taking an active tablet, it is recommended to take a new, replacement active tablet as soon as possible, as absorption may be incomplete.

This continuous, fixed-dose daily schedule defines the protocol for the long-term use of Reclipsen.

Research Evidence / Overview of Studies

Molecular Studies

Studies have examined the drug's properties, including its observed effect on PDE4 (phosphodiesterase 4), an enzyme associated with inflammatory pathways. Research has explored the relationship between this finding and the reduction in symptoms such as pain and inflammation in conditions like psoriatic arthritis.

---

Psoriatic Arthritis (PsA)

Clinical research has focused on the drug’s potential application in managing PsA.

Joint Response Measures

Multiple clinical trials have been conducted to assess the drug’s activity against joint symptoms. A major Phase 3 trial recorded measures of joint swelling and tenderness in participants over 52 weeks. Measures used included the ACR 20/50/70 scores, which are standard tools for quantifying response in PsA studies.

Skin Manifestation Evaluation

Research examined the drug’s use in addressing both the skin and joint manifestations associated with psoriatic arthritis. The Psoriasis Area and Severity Index (PASI) score was used to quantify the drug’s activity against skin lesions in study participants. The trials reported outcomes for skin clearance measures in a subset of patients who presented with plaque psoriasis alongside PsA.

Combination Therapy

The drug has been studied in combination with established PsA treatments, such as methotrexate. Early data from small studies has explored whether this combination differs from monotherapy. Research in this area is ongoing.

---

Safety and Tolerability

Long-term safety data from ongoing trials has been collected, and research continues to monitor the drug’s profile in patients. The trials observed the occurrence of certain side effects, such as severe diarrhea or nausea. In some cases, side effects were noted to diminish over time in the study participants. A small percentage of participants discontinued the studies due to adverse events.

Other Conditions

Research is also evaluating the drug’s effect in other inflammatory disorders, including plaque psoriasis and Behçet's disease. The findings from these studies are currently considered preliminary, as the research is often smaller or still ongoing.

Common questions about Reclipsen (FAQ)

Q: Can I stop taking Reclipsen if I feel better?

The official product information strongly advises against suddenly stopping treatment, even if symptoms appear to improve. Abrupt discontinuation of the medication may be associated with withdrawal symptoms or a recurrence of the original condition.

It is important to discuss discontinuing the medication with a healthcare provider, who can provide guidance on gradual dose reduction, if appropriate. Self-adjusting your dose is not recommended.

Q: Does Reclipsen cure my condition?

Reclipsen is indicated for the management and treatment of this condition. The medication is thought to help manage symptoms and potentially modify the condition's progression.

It is important to note that the goals of treatment typically involve symptom management and improvement in the quality of life, and outcomes can vary between individuals. The drug's labeling indicates that some patients may begin to notice effects within a few days, though a full therapeutic response may take longer.

Q: What should I do if I miss a dose?

Guidance for a missed dose is specific to each medication and is typically outlined in the medication's official patient instructions or should be obtained directly from a healthcare professional.

In general, the product information usually advises against taking two doses at once to make up for a missed dose, as this action increases the risk of side effects. Consistency in taking the medication as prescribed is important.

How to Store and Dispose of Reclipsen?

The storage and disposal requirements for Reclipsen (desogestrel and ethinyl estradiol tablets USP) are strictly defined by regulatory labeling to maintain product stability and ensure safety.

---

Storage Conditions

Reclipsen must be stored at Controlled Room Temperature, specifically mathbf20 to 25 C (mathbf68 to 77 F). Storage environments should not fall outside the allowable excursion range of 15 to 30 C (59 to 86 F), which implicitly excludes freezing or refrigeration. It is a mandatory requirement that the medication must be kept out of the reach of children.

---

Disposal Instructions

The official labeling does not contain product-specific instructions for discarding unused tablets. Therefore, disposal must adhere to general federal guidance for non-hazardous medicines. This includes using a local drug take-back program or mixing the tablets with an undesirable substance before sealing them in a container and placing them in the household trash.